Codice QR

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia

Abstract Aims In previous randomized controlled trials, the use of tolvaptan (TLV) at a fixed dose of 30 mg/day for 1 year did not provide renal benefits in patients with heart failure (HF). This retrospective, cohort study examined the renoprotective effects of long‐term, flexible‐dose, and lower‐d...

Descrizione completa

Salvato in:
Autori principali: Tatsufumi Oka, Takayuki Hamano, Tomohito Ohtani, Yohei Doi, Karin Shimada, Ayumi Matsumoto, Satoshi Yamaguchi, Nobuhiro Hashimoto, Masamitsu Senda, Yusuke Sakaguchi, Isao Matsui, Kei Nakamoto, Fusako Sera, Shungo Hikoso, Yasushi Sakata, Yoshitaka Isaka
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2021-12-01
Serie:ESC Heart Failure
Soggetti:
Tolvaptan
Heart failure (HF)
Renal function
Hyponatremia
Renal benefits
Accesso online:https://doi.org/10.1002/ehf2.13507
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi